Japan Dabigatran Market was valued at USD 0.4 Billion in 2022 and is projected to reach USD 0.6 Billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030.
Dabigatran etexilate, marketed as Pradaxa®, is a direct thrombin inhibitor that has significantly impacted stroke prevention in patients with non-valvular atrial fibrillation (NVAF) in Japan. Since its approval by the Ministry of Health, Labour and Welfare in January 2011, it has provided an alternative to traditional vitamin K antagonists like warfarin. citeturn0search1
The Japanese market for dabigatran is characterized by a diverse range of patient demographics and clinical profiles. A descriptive analysis of two real-world studies, the J-dabigatran surveillance and the Japanese study on current Anticoagulation therapies for Patients with NVAF (JAPAF), revealed notable findings: - **Patient Demographics**: The studies included 1,270 patients from the J-dabigatran surveillance and 3,011 from the JAPAF study. The mean age was 71.1 years for the former and 74.1 years for the latter, with approximately 66% male participants in both cohorts. citeturn0search2 - **Anticoagulant Therapy Initiation**: Among patients initiating dabigatran, 31.8% had switched from warfarin, while 68.2% were new initiations. In the JAPAF study, 82.5% were on warfarin, 10.3% on rivaroxaban, and 21% on antiplatelet therapy. citeturn0search2 - **Stroke and Bleeding Risk Profiles**: Patients on dabigatran exhibited varying risks, with 41.4% on the 110 mg twice daily (BID) dose and 57.5% on the 150 mg BID dose having a CHADS₂ score of 0 or 1, indicating low to intermediate stroke risk. Additionally, 41.5% on the 110 mg BID and 18.7% on the 150 mg BID had a HAS-BLED score ≥3, highlighting a higher risk of bleeding. In contrast, patients on warfarin, rivaroxaban, or antiplatelets had different distributions of stroke and bleeding risks. citeturn0search2 These insights underscore the importance of personalized anticoagulant therapy in Japan, considering individual patient characteristics and risk profiles. The data also reflect the dynamic landscape of anticoagulant choices, influenced by factors such as efficacy, safety, and patient preference. As the market evolves, ongoing surveillance and research will be crucial in optimizing treatment strategies for NVAF patients.
Get an In-Depth Research Analysis of the Japan Dabigatran Market Size And Forecast [2025-2032]
Pfizer
Bayer Healthcare
GlaxoSmithKline
Boehringer Ingelheim
Aspen Holdings
Bristol-Myers Squibb Company
Teva Pharmaceutical Industries
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the Japan Dabigatran Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the Japan Dabigatran Market
Atrial Fibrillation
Venous Thromboembolism
Postoperative Thromboprophylaxis
Myocardial Infarction
Capsules
Injectables
Oral Solutions
Tablet Formulations
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Healthcare Institutions
Adults
Elderly
Pediatric Population
Patients with Comorbidities
Branded Products
Generics
Combination Therapies
Extended-Release Formulations
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
For More Information or Query, Visit @ Japan Dabigatran Market Research Analysis
1. Introduction of the Japan Dabigatran Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Japan Dabigatran Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Japan Dabigatran Market, By Type
6. Japan Dabigatran Market, By Application
7. Japan Dabigatran Market, By Geography
Asia-Pacific
China
Japan
Korea
India
Australia
Indonesia
Thailand
Philippines
Malaysia and Vietnam
8. Japan Dabigatran Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Research and Consulting firm servicing over 5000+ clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/